Bordetella pertussis is a bacterium that is the causative agent of whooping cough, a highly contagious respiratory disease. This bacterium produces several toxins, including Adenylate Cyclase Toxin, Dermonecrotic Toxin, Entericidin B-Like Bacteriolytic Toxin, and Pertussis Toxin Subunits.

Adenylate Cyclase Toxin is a multifunctional toxin that can inhibit host immune cells and stimulate the release of calcium ions from host cells, which can contribute to the pathogenesis of whooping cough.

Dermonecrotic Toxin is a heat-labile toxin that is known to cause dermal necrosis in experimental animals. This toxin is also involved in the adherence of the bacterium to host cells and the evasion of the host immune system.

Entericidin B-Like Bacteriolytic Toxin is a pore-forming toxin that can cause lysis of bacterial cells. This toxin may contribute to the ability of Bordetella pertussis to compete with other bacterial species in the host respiratory tract.

Pertussis Toxin is a multi-subunit AB toxin that is known to inhibit host immune cells and stimulate the release of histamine, which can contribute to the symptoms of whooping cough. The five subunits of Pertussis Toxin are S1, S2, S3, S4, and S5.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, successful recombinant protein expression in heterologous expression systems depends on various factors, including codon preference, RNA secondary structure, and GC content. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins. Compared to pre-optimization, more experimental results demonstrated that the expression level was dramatically increased, ranging from two to a hundred times depending on the gene.

Bordetella pertussis cDNA and recombinant antigen can be used as a detection tool to determine vaccine-induced and natural immunity. In a laboratory setting, cDNA and recombinant antigens can be used to measure the level of antibodies in a sample, which is then compared to a known value to determine the presence of immunity. This method has been used to study the efficacy of different vaccines, as well as the level of protection provided by natural immunity. In addition, cDNA and recombinant antigen can be used to detect the presence of other microorganisms, such as Mycobacterium tuberculosis, to identify